Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
Novo Nordisk (NVO) Stock Price & Analysis
5,514 Followers
NVO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$74.92 - $148.15
Previous Close$142.37
Volume3.66M
Average Volume (3M)3.78M
Market Cap
$627.04B
Enterprise Value$626.57B
Total Cash (Recent Filing)kr30.23B
Total Debt (Recent Filing)kr27.01B
Price to Earnings (P/E)49.0
Beta0.44
Next Earnings
Aug 07, 2024EPS Estimate
$0.75Last Dividend Ex-Date
Mar 22, 2024Dividend Yield0.69%
Share Statistics
EPS (TTM)2.90
Shares Outstanding4,462,229,293
10 Day Avg. Volume3,256,440
30 Day Avg. Volume3,779,057
Standard Deviation0.06
R-Squared0.14
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)13.72
Price to Sales (P/S)7.40
Price to Cash Flow (P/CF)16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$142.36Price Target Upside>-0.01% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Novo Nordisk News
Bulls Say, Bears Say
Bulls Say
EarningsToday's data a positive for Novo shares as investors watch the company execute on its longer-term plan for diversification with Mim8 representing a potential peak unadjusted revenue opportunity.
InvestmentPresentation of the full FLOW kidney outcomes data and the announcement of plans to invest $4.1B in expanding fill finish capacity continue to solidify Novo's position as one of two leaders in the obesity metabolic space.
Pipeline DiversificationPositive Mim8 Data in Hemophilia A points to key portfolio diversification for Novo, with a likely competitive asset to Roche's Hemlibra.
Bears Say
Clinical Trial ResultsAcquired asset, ocedurenone, fails in pre-specified interim analysis for Ph 3 CLARION-CKD trial.
EarningsObesity care demand has continued to climb, revenue fell short of expectations with Wegovy missing estimates by 10%.
Financial PerformanceNovo will recognize a DKK 5.7B impairment charge and will look to reevaluate other current trials for indication expansion.
---
Ownership Overview
0.00%
Insiders
1.62% Mutual Funds
0.10% Other Institutional Investors
98.27% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $74.92 and its highest was $148.15 in the past 12 months.
What is Novo Nordisk’s market cap?
Currently, no data Available
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 07, 2024 which is in 30 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 02, 2024. The company reported $0.814 earnings per share for the quarter, beating the consensus estimate of $0.752 by $0.062.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.66 which represents an annual dividend yield of 0.69%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is $0.75.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.814 in its last earnings report, beating expectations of $0.752. Following the earnings report the stock price went down -4.017%.
Which hedge fund is a major shareholder of Novo Nordisk?
Among the largest hedge funds holding Novo Nordisk’s share is Fisher Asset Management LLC. It holds Novo Nordisk’s shares valued at 2B.
---
Novo Nordisk Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$142.36 (>-0.01% Downside)
$142.36 (>-0.01% Downside)
Blogger Sentiment
Bullish
NVO Sentiment 84%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.48%
12-Months-Change
Fundamentals
Return on Equity
99.99%
Trailing 12-Months
Asset Growth
18.69%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NVO Company Deck
---
NVO Earnings Call
Q1 2024
0:00 / 0:00
---
NVO Stock 12 Month Forecast
Average Price Target
$142.36
▼(>-0.01% Downside)
Technical Analysis
Best Analysts Covering NVO
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+29.75%
reiterated a buy rating 2 months ago
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.75% per trade.
---